PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Thymus neoplasm

Drugs in development · updated 30 October 2026

Thymus neoplasm: drugs in development

As of 30 October 2026 there are 8 active clinical trials (recruiting or ongoing, phases I–III) on 10 drugs for thymus neoplasm. 6 are experimental, that is not yet approved in the United States.

8Active trials
6Experimental drugs
0Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
Bintrafusp AlfaM7824II1NCT04417660
IvonescimabAK112II1NCT06750952
KC1036II1NCT05683886
PT-112II1NCT05104736
[68Ga]Ga-FAPI-46Gallium Ga 68 FAPi-46I1NCT04459273
KFA115I1NCT05544929

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
EverolimusRAD001, EveroliumusIII1NCT05918302
CyclophosphamideCyclophosphamid, CytoxanI1NCT06885697
FludarabineFludara, FLUDARABINI1NCT06885697
PembrolizumabKEYTRUDA, MK-3475I1NCT05544929

Sorted by most advanced phase and number of active trials.

All 10 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Specific forms

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D013953 “Thymus Neoplasms”.

ItalianoFrançaisDeutsch